Sign In
Buy ADAP
$0.0549
+0 (+0%)
At Close: Feb 20, 2026
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
12:47pm, Tuesday, 16'th Jan 2024
Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.
Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; projecte
First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug Administration Afami-cel data demonstrate better outcomes for people with synovial sarcoma compared to histo
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
12:01pm, Thursday, 30'th Nov 2023
Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.
Adaptimmune Receives Transfer of IND for Lete-cel Program
08:00am, Wednesday, 29'th Nov 2023
Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma fr
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:19am, Monday, 13'th Nov 2023
Adaptimmune Therapeutics PLC (ADAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising
Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript
11:45am, Wednesday, 08'th Nov 2023
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Juli Miller – Investor Relations Adrian Rawcliffe – Chief Executive Of
Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing
07:32pm, Tuesday, 07'th Nov 2023
The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.60, representing a +1.5% change from its previous close.
Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights
07:33pm, Friday, 27'th Oct 2023
The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.55, representing a -1.79% change from its previous close.
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
08:06am, Wednesday, 25'th Oct 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report fin
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
01:24pm, Thursday, 03'rd Aug 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial
Buy 5 Top-Ranked Stocks With Rising P/E in July
09:20am, Thursday, 06'th Jul 2023
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and
GSK Announces Extension of FDA Review for Rare Blood Therapy
11:43am, Monday, 19'th Jun 2023
GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.
Down -22.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Adaptimmune Therapeutics PLC (ADAP)
10:40am, Tuesday, 30'th May 2023
The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wa
Adaptimmune Therapeutics plc (ADAP) Q1 2023 Earnings Call Transcript
01:09pm, Friday, 12'th May 2023
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Offic
